SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is currently receiving attention as traders debate whether the stock represents a long-term "buy" at its 52-week lows or a "value trap" hindered by declining consumer demand and operational issues. While some market participants express skepticism over the company's competitiveness and pricing power, others view the current valuation and dividend yield as a significant entry opportunity for a defensive blue-chip asset.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Investors are largely divided on the asset, with many holding long-term conviction based on the network's decentralized cloud and AI infrastructure, while others remain frustrated by persistent price declines and token dilution concerns. The conversation is currently dominated by long-term holders debating the project's technological utility versus its historical market performance.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Traders are discussing a potential short squeeze, citing high short interest as a percentage of the float and significant institutional ownership as evidence of a structural trap for short sellers. While some participants are optimistic about the company's turnaround efforts, others express frustration over recent price volatility and lack of trading volume.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is trending as the community highlights its role in the AI data center buildout, specifically regarding power delivery and thermal management solutions. Traders are expressing bullish sentiment, focusing on the company's strong guidance, backlog growth, and expansion in global manufacturing capacity to meet rising demand from hyperscalers.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

The stock is attracting attention due to high short interest and market anticipation of a signed Power Purchase Agreement (PPA) and tenant deal for its Texas data center project. Traders are largely focused on a potential short squeeze, citing significant institutional accumulation and the belief that the company's off-grid energy strategy provides a unique advantage in the data center market.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

The stock is receiving attention following a significant decline after the failure of its Phase 3 Aspire trial for an Angelman syndrome treatment, which missed both primary and secondary endpoints. While some investors view the sell-off as a severe overreaction and a buying opportunity due to the company's remaining commercial portfolio and upcoming catalysts, others express concern over the pipeline setback and the resulting shift in focus toward commercial execution and cost-cutting.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending primarily due to anticipation surrounding its second-quarter earnings report and corporate update, with investors focusing on potential revenue guidance and the impact of the DefenCath roll-out within large dialysis organizations. While some traders express frustration with the recent stock performance, others are highlighting institutional accumulation and upcoming pipeline milestones as catalysts for long-term optimism.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is trending as investors debate the asset's long-term potential, citing its low circulating supply and institutional pivot while some express frustration over persistent price stagnation compared to other DeFi tokens. Community members are divided, with some actively accumulating on dips while others criticize the lack of significant momentum and label the project's price action as stagnant.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is trending following the announcement that the stock will be added to the S&P 500 index during the quarterly rebalance. While the catalyst has driven significant bullish sentiment and retail interest, market participants are divided between expectations of a sustained rally driven by mechanical demand from index-tracking funds and concerns regarding a potential 'sell the news' pullback similar to previous index additions.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing downward volatility following earnings as investors weigh the company's robust revenue growth and expansion plans against concerns over slowing same-store sales guidance and the costs associated with acquiring former Salad and Go locations. While the community remains divided between those viewing the pullback as a buying opportunity given the company's aggressive growth trajectory and those wary of its premium valuation in a challenging consumer environment, many traders are closely watching support levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of "Buy" by Brokerages

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight ratings firms that are covering the company, Marketbeat reports. One...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of "Buy" by Analysts

Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) have earned an average rating of "Buy" from the eight analysts that are presently covering the company, MarketBeat reports. One...

HC Wainwright Issues Positive Estimate for IKT Earnings

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Free Report) - Equities researchers at HC Wainwright increased their Q1 2026 earnings per share estimates for Inhibikase Therapeutics in a research report...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Analysts

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has received a consensus recommendation of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat Ratings...

Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Strong-Buy" at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded Inhibikase Therapeutics to a "strong-buy" rating in a report on Wednesday...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Update

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling...

Inhibikase Therapeutics (NYSE:IKT) Coverage Initiated at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH initiated coverage on Inhibikase Therapeutics in a research report on Wednesday. They set a "buy" rating and a $4.00 target price for the company...

FY2025 Earnings Forecast for IKT Issued By Lifesci Capital

Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) - Stock analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Inhibikase Therapeutics in a report issued on Monday...

Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4% - Still a Buy?

Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 4.4% - Time to Buy...

Inhibikase Therapeutics (NASDAQ:IKT) Upgraded by Lifesci Capital to "Strong-Buy" Rating

Lifesci Capital raised Inhibikase Therapeutics to a "strong-buy" rating in a report on Monday...

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Wilmington, DE.

Inhibikase Therapeutics Inc

Bullish Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Current Price	$2.50
Prev Close	$2.52
Open	$2.49
Dividend Yield	0.00%
50-Day Moving Average	$2.27
Beta	1.20
Avg. Volume	486,072.70
PE Ratio	-5.73

52-Week High	$2.61
52-Week Low	$1.33
Market Capitalization	$351.63M
EPS (Annual)	-$0.4909
Price to Book	2.15
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

IKT Fundamentals